Donny Stokes, MD
Cardiovascular Disease · Jackson, MSNPI 1821290990
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $170,768 of the $206,630 with a category attached, or 82.6%. 44 manufacturers reported payments, led by Boehringer Ingelheim at 34.9% of the total. Reporting peaked in 2021 at $83,075 and has fallen 91.3% since, to $7,248 in 2025. Among cardiovascular disease clinicians in MS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,301 payments — averaging $158.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$72K
- AstraZeneca$56K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$38K
- Esperion Therapeutics, Inc.$11K
- Lilly USA, LLC$9K
- Abiomed$4K
- plus $17K from 38 others
Across 7 payments — averaging $10,027 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$70K
What the payments were for
- Consulting fees$4500%
- Speaking & faculty fees$170,76883%
- Travel & lodging$5,5263%
- Food & beverage$29,83314%
- Education$530%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$78,534
- FARXIGA$53,700
- LifeVest$34,500
- NEXLIZET$10,253
- NEXLETOL$10,253
- Barostim Neo System$2,991
- Impella$994
- LINQ II$387
- WATCHMAN Access System$385
- Reveal LINQ$314
- XARELTO$250
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$144
- GENERAL - THERAPIES$133
- Repatha$125
- (5044) MCOT$125
- VERQUVO$122
- FFRct$121
- (9520) IGT Devices Undivided$113
- Indigo System$111
- Watchman$108
How this compares
$206,630 in reported general payments places this provider in the 95th percentile of 144 cardiovascular disease providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 1,080 | $788,570 |
| JardianceEmpagliflozin | 481 | $392,698 |
| EntrestoSacubitril/Valsartan | 305 | $294,313 |
| FarxigaDapagliflozin Propanediol | 228 | $159,934 |
| Repatha SureclickEvolocumab | 230 | $156,867 |
| XareltoRivaroxaban | 146 | $124,092 |
| BrilintaTicagrelor | 87 | $61,642 |
| Praluent PenAlirocumab | 85 | $52,965 |
| Ranolazine ErRanolazine | 353 | $19,731 |
| Rosuvastatin Calcium | 1,342 | $10,931 |
| Metoprolol Succinate | 1,119 | $9,745 |
| Ezetimibe | 578 | $8,429 |
| CorlanorIvabradine Hcl | 11 | $7,689 |
| NexletolBempedoic Acid | 11 | $6,749 |
| Atorvastatin Calcium | 677 | $4,530 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $541 | $788,5701,080 claims |
| Boehringer IngelheimJardiance | $72,128 | $392,698481 claims |
| NovartisEntresto | $2,514 | $294,313305 claims |
| AstraZenecaFarxiga, Brilinta | $55,663 | $221,577315 claims |
| Johnson & JohnsonXarelto | $734 | $124,092146 claims |
| AmgenCorlanor | $1,381 | $7,68911 claims |
| Esperion Therapeutics, Inc.Nexletol | $10,543 | $6,74911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 144 cardiovascular disease providers in Mississippi.
Other cardiovascular disease in Jackson
- James BenslerJackson$64K
- Michael HallJackson$54K
- Tahsin QarqishJackson$39K
- Christopher LatourJackson$33K
- Varun SardarJackson$31K
- Olurotimi BaderoJackson$20K
- Michael PaymentJackson$16K
- James HaysJackson$16K
- Douglas HarkinsJackson$14K
- Aditya SabharwalJackson$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.